Literature DB >> 3522832

Cefuroxime versus ampicillin plus chloramphenicol in childhood bacterial meningitis: a multicenter randomized controlled trial.

W A Marks, H R Stutman, M I Marks, J S Abramson, E M Ayoub, S A Chartrand, F E Cox, W A Geffen, C J Harrison, D Harrison.   

Abstract

In a multicenter randomized trial, 107 children with bacterial meningitis were initially given either cefuroxime or ampicillin plus chloramphenicol. Patients were alternately assigned to 7- or 10-day courses of the designated antimicrobial regimen. CSF isolates included Haemophilus influenzae type b (89, of which 25% were beta-lactamase positive), Streptococcus pneumoniae, and Neisseria meningitidis. Although mean CSF bactericidal titers against Haemophilus isolates were 1:6 in each treatment group, H. influenzae was cultured from CSF in four of 39 patients receiving cefuroxime, 24 to 48 hours after initiation of therapy, compared with none of 40 patients given ampicillin plus chloramphenicol (P = 0.11). Clinical cure rates were similar (95%); one death occurred in each group. One child given cefuroxime had persistent meningitis after 5 days of therapy, and mastoiditis with secondary bacteremia developed in one on day 10. Three patients had relapse or reinfection. One patient who received cefuroxime for 10 days had a relapse of epiglottitis 17 days later, and of the patients given ampicillin plus chloramphenicol, one had a relapse of meningitis 1 week after 7 days of therapy, and bacteremia developed in one 42 days after completion of 10 days of therapy. No increase in either in-hospital complications or relapses occurred with a 7-day treatment course. Proof of the equivalence of the antibiotic regimens and the efficacy of 7-day courses of treatment, as well as the consequences of delayed CSF sterilization, will require additional investigation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3522832     DOI: 10.1016/s0022-3476(86)80591-1

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Antibiotic choices for meningitis beyond the neonatal period.

Authors:  N J Klein; R S Heyderman; M Levin
Journal:  Arch Dis Child       Date:  1992-02       Impact factor: 3.791

Review 3.  Third generation cephalosporins versus conventional antibiotics for treating acute bacterial meningitis.

Authors:  K Prasad; A Kumar; P K Gupta; T Singhal
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17

4.  Bacterial meningitis in India: an IJP survey.

Authors:  S K Kabra; P Kumar; I C Verma; D Mukherjee; B H Chowdhary; S Sengupta; R N Singh; S P Khatua; N Miglani; K M Sehai
Journal:  Indian J Pediatr       Date:  1991 Jul-Aug       Impact factor: 1.967

5.  Initial therapy for bacterial meningitis. Infectious Diseases and Immunization Committee, Canadian Paediatric Society.

Authors: 
Journal:  CMAJ       Date:  1990-02-15       Impact factor: 8.262

6.  Novel approaches to therapy of meningitis.

Authors:  G H McCracken
Journal:  Bull N Y Acad Med       Date:  1987 Jul-Aug

7.  Disk diffusion interpretive criteria for extended-spectrum cephalosporins with Haemophilus influenzae.

Authors:  J H Jorgensen; L A Maher; J S Redding
Journal:  J Clin Microbiol       Date:  1988-09       Impact factor: 5.948

8.  Bacterial meningitis in the 1980s, or one drug or many?

Authors:  C E Cherubin; R H Eng
Journal:  West J Med       Date:  1987-09

9.  Susceptibility of Haemophilus influenzae type b to ampicillin-sulbactam.

Authors:  P H Azimi; M G Dunphy
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

10.  Value of cerebrospinal fluid examination in the diagnosis of meningitis in the newborn.

Authors:  L Hristeva; I Bowler; R Booy; A King; A R Wilkinson
Journal:  Arch Dis Child       Date:  1993-11       Impact factor: 3.791

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.